Cipla Secures Exclusive US Licensing for Keytruda Biosimilar from Qilu Pharmaceutical
Cipla Ltd 路 Press Release 路 04 Sept 2026, 1:36 am
Cipla Secures Exclusive US Licensing for Keytruda Biosimilar from Qilu Pharmaceutical On 3rd Sep'26, Cipla announced an exclusive US licensing and supply partnership with Qilu Pharmaceutical for QL2107, a biosimilar to Keytruda (pembrolizumab). Under the agreement, Qilu assumes responsibility for development, regulatory registration, and manufacturing supply, while Cipla USA secures commercialization rights. This partnership enables Cipla to leverage its existing US commercial infrastructure to expand its oncology-focused biosimilar portfolio. The strategic addition of this asset significantly strengthens Cipla's US pipeline, positioning the company to capture share in a high-value market upon regulatory approval.
Original exchange filing (PDF)
More announcements from Cipla Ltd
- Please find enclosed intimation 路 18 Nov 2026
- Please find enclosed disclosure. 路 17 Nov 2026
- Appointment of Mr Vikram Janakiraman, as the Global Chief Technical Operating Officer, designated as a Senior Management Personnel of the Company, with effect from 7th December, 2026. 路 04 Nov 2026
- Please find enclosed Earnings Call Transcript - Q2FY27 路 30 Oct 2026
- In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 29th October, 2026 .... 路 30 Oct 2026
- Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the .... 路 28 Oct 2026
- Please find intimation in relation to grant of ESOS and ESAR. 路 27 Oct 2026
- Please find enclosed the intimation for Appointment of Ms Rashmi Joshi as an additional and independent director of the Company w.e.f. 27th October, 2026 for a period of 5 years. 路 27 Oct 2026
